 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Addex Pharmaceuticals
|
-
Addex Appoints Laurent Massuyeau as Head of Business Development
(04/22/2008)
Addex Pharmaceuticals announced the appointment of Laurent Massuyeau as head of business development.Mr. Massuyeau joins Addex from Idenix Pharmaceuticals Inc., where he was executive director of European commercial operations. He brings to Addex 7 ...
-
Addex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
(02/27/2008)
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
Addex Pharmaceuticals announced that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The ...
-
Addex Announces ADX10059 Phase IIa Acute Anxiety Data
(01/04/2008)
Addex Pharmaceuticals announced that ADX10059 did not reduce acute anticipatory anxiety in a small Phase IIa study in patients with dental anxiety. However, some signs of anxiolytic activity were observed. Development of ADX10059 for gastroesophageal...
-
Addex and Merck & Co., Inc. Collaborate to Develop Drugs for Parkinson's Disease
(12/04/2007)
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
Addex Pharmaceuticals announced that it has entered an exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd) with the goal of developing a new class of orally available drugs, ...
-
Addex commences Phase II clinical trials programme compound ADX10059 for use against migraine and anxiety
(09/04/2006)
Addex Pharmaceuticals announced the start of the Phase II development programme of its lead compound ADX10059. This announcement follows the successful completion of three Phase I trials, in over 100 healthy subjects, which demonstrated good ...
-
Addex Pharmaceuticals enters into Collaboration with Ortho-McNeil Pharmaceutical to Develop Novel Treatments
(01/18/2005)
Addex Pharmaceuticals announced that it has entered an exclusive worldwide research collaboration and licence agreement with Ortho-McNeil Pharmaceutical, Inc. to discover, develop and commercialize novel compounds modulating allosterically G-Protein ...
Additional information
Addex Pharmaceuticals
Plan-les-Ouates, Geneva, Switzerland
Company
|
|
|
|
|
|
Top
